Current Treatment Options in Neurology

, Volume 15, Issue 4, pp 519-528

First online:

New Treatment Options for Lennox-Gastaut Syndrome

  • Monica E. LemmonAffiliated withDepartment of Neurology, The Johns Hopkins Hospital Email author 
  • , Eric H. KossoffAffiliated withDepartment of Neurology, The Johns Hopkins Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Opinion statement

Lennox-Gastaut syndrome (LGS) is one of the most difficult epilepsy syndromes to treat, and many children are refractory to standard treatment regimens. Valproic acid, topiramate, and lamotrigine are considered first-line therapies. Newer agents, including clobazam and rufinamide, are promising additions to the current treatment options. The ketogenic diet and vagus nerve stimulation are important adjuncts, with increasing evidence to support their use. Corpus callosotomy should be considered in refractory cases. Finally, focal resective surgery should be considered in patients with lesional disease, although for most patients with LGS this is unlikely to be the case.


Lennox-Gastaut syndrome LGS Epilepsy Treatment Clobazam Rufinamide Topiramate Lamotrigine Levetiracetam Valproic acid Zonisamide Felbamate Ketogenic diet Vagus nerve stimulator Corpus callostomy